ABSTRACT
Kaposi’s sarcoma (KS), the most common acquired immunodeficiency syndrome (AIDS)-associated cancer, was one of the first conditions recognized as an opportunistic complication of human immunodeficiency virus type-1 (HIV) infection (1). Unlike many of the infectious sequelae of HIV infection, which occur primarily in patients with severe immune impairment and CD4 lymphocyte depletion, KS can occur at almost any stage of HIV infection, but its incidence rises as immune function declines (4-6).
